RE:RE:RE:RE:RE:RE:RE:Unpack"I would bet they did not explore a single other option than uniting Gilles..."
Gilles knows AEZS. Invest in what you know. The relicensing of AEZS's growth hormone deficiency test could be very interesting given what Novo Nordisk invested and now approval for its most important market(children) may be near. Novo Nordisk invested more than the combined value of the merged companies(CZO, AEZS) and with potential pediatric approval it is now ready for its more important market. Gilles shold know how talks concerning relicensing have gone.
Gilles might have picked up AEZS's cash, and pipeline at the bottom of the market in a very significant deal that adds scale ahead of PGX deals, etc. And cash.